Login / Signup

Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it!

Daniel R Van LangenbergAbhinav Vasudevan
Published in: Alimentary pharmacology & therapeutics (2019)
Keyphrases
  • ulcerative colitis
  • adverse drug
  • drug induced
  • patients with inflammatory bowel disease